Long-term outcomes of 307 patients after complete thymoma resection

Yuan, Zuyang; Gao, Shugeng; Mu, Jianjun; Xue, Qi; Mao, Yousheng; Wang, Dali; Zhao, Jun; Gao, Yushun; Huang, Jinfeng; He, Jie

doi:10.1186/s40880-017-0213-8

Cited by 18 publications

(17 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The majority of tumours were benign, with only 19% spreading outside the capsule. This cohort seemed to have a more benign course than previously published series of thymoma patients not selected on the basis of hypogammaglobulinaemia, where more than half of patients’ tumours were invasive and 28% of patients had died . In our cohort, only nine patients (11%) had thymic carcinoma and seven patients (9%) had died, two from their metastatic thymoma and three from infections.…”

Section: Discussionmentioning

confidence: 51%

Clinical and laboratory features of seventy-eight UK patients with Good’s syndrome (thymoma and hypogammaglobulinaemia)

Zaman

Huissoon

Buckland

et al. 2018

Clinical and Experimental Immunology

View full text Add to dashboard Cite

Good's syndrome (thymoma and hypogammaglobulinaemia) is a rare secondary immunodeficiency disease, previously reported in the published literature as mainly individual cases or small case series. We use the national UK-Primary Immune Deficiency (UKPID) registry to identify a large cohort of patients in the UK with this PID to review its clinical course, natural history and prognosis. Clinical information, laboratory data, treatment and outcome were collated and analysed. Seventy-eight patients with a median age of 64 years, 59% of whom were female, were reviewed. Median age of presentation was 54 years. Absolute B cell numbers and serum immunoglobulins were very low in all patients and all received immunoglobulin replacement therapy. All patients had undergone thymectomy and nine (12%) had thymic carcinoma (four locally invasive and five had disseminated disease) requiring adjuvant radiotherapy and/or chemotherapy. CD4 T cells were significantly lower in these patients with malignant thymoma. Seventy-four (95%) presented with infections, 35 (45%) had bronchiectasis, seven (9%) chronic sinusitis, but only eight (10%) had serious invasive fungal or viral infections. Patients with AB-type thymomas were more likely to have bronchiectasis. Twenty (26%) suffered from autoimmune diseases (pure red cell aplasia, hypothyroidism, arthritis, myasthenia gravis, systemic lupus erythematosus, Sjögren's syndrome). There was no association between thymoma type and autoimmunity. Seven (9%) patients had died. Good's syndrome is associated with significant morbidity relating to infectious and autoimmune complications. Prospective studies are required to understand why some patients with thymoma develop persistent hypogammaglobulinaemia.

show abstract

Section: Discussionmentioning

confidence: 51%

Clinical and laboratory features of seventy-eight UK patients with Good’s syndrome (thymoma and hypogammaglobulinaemia)

Zaman

Huissoon

Buckland

et al. 2018

Clinical and Experimental Immunology

View full text Add to dashboard Cite

show abstract

“…Then the up-regulated metabolic genes and their relatedness in each cancer type are used to construct networks for each model and methods, where nodes represent genes, and two genes are connected if the MR of their relatedness is among top three. We collect 21 genes, including eight rate-limiting enzyme genes for glutaminolysis and 13 genes directly catalyzing reactions of glutamine or glutamate, defined as the gene markers for glutamine and glutamate metabolism (see Table 3), inspired by a recent study 85 . After identifying modules containing up-regulated gene markers, the pathway enrichment analysis is conducted on such modules to predict metabolic pathways directly influenced by increased glutamine and glutamate metabolism, which are the enriched with up-regulated gene markers, as shown in Fig.…”

Section: Resultsmentioning

confidence: 99%

Using Machine Learning to Measure Relatedness Between Genes: A Multi-Features Model

Wang

Yang

Zhao

et al. 2019

Sci Rep

View full text Add to dashboard Cite

Measuring conditional relatedness between a pair of genes is a fundamental technique and still a significant challenge in computational biology. Such relatedness can be assessed by gene expression similarities while suffering high false discovery rates. Meanwhile, other types of features, e.g., prior-knowledge based similarities, is only viable for measuring global relatedness. In this paper, we propose a novel machine learning model, named Multi-Features Relatedness (MFR), for accurately measuring conditional relatedness between a pair of genes by incorporating expression similarities with prior-knowledge based similarities in an assessment criterion. MFR is used to predict gene-gene interactions extracted from the COXPRESdb, KEGG, HPRD, and TRRUST databases by the 10-fold cross validation and test verification, and to identify gene-gene interactions collected from the GeneFriends and DIP databases for further verification. The results show that MFR achieves the highest area under curve (AUC) values for identifying gene-gene interactions in the development, test, and DIP datasets. Specifically, it obtains an improvement of 1.1% on average of precision for detecting gene pairs with both high expression similarities and high prior-knowledge based similarities in all datasets, comparing to other linear models and coexpression analysis methods. Regarding cancer gene networks construction and gene function prediction, MFR also obtains the results with more biological significances and higher average prediction accuracy, than other compared models and methods. A website of the MFR model and relevant datasets can be accessed from http://bmbl.sdstate.edu/MFR.

show abstract

“…The most frequently reported relapses are those at pleural or otherwise intrathoracic sites, while distant metastases are rare. 5 So far, to our knowledge, no other studies have been conducted to investigate the changes in AChR-Ab titers before and after thymectomy in a large cohort of TAMG patients. Kim et al analyzed AChR-Ab titers in both thymomatous and nonthymomatous patients and they found a significant decrease in AChR-Ab titer after thymectomy in nonthymomatous MG but not in patients with thymoma, suggesting that the pathogenic role of the thymus differs according to pathology.…”

Section: Introductionmentioning

confidence: 99%

Thymoma‐associated myasthenia gravis: Clinical features and predictive value of antiacetylcholine receptor antibodies in the risk of recurrence of thymoma

et al. 2020

View full text Add to dashboard Cite

Background: Thymoma-associated myasthenia gravis (TAMG) is one of the subtypes of myasthenia gravis with autoantibodies against the acetylcholine receptor (AChR-Ab). We analyzed the clinical features of our cohort of TAMG patients and the changes in AChR-Ab titer before and after thymectomy in order to identify factors predicting thymoma relapses. Methods: We retrospectively assessed: age of MG onset, MG clinical status according to MGFA (Myasthenia Gravis Foundation of America), epoch of thymectomy, post-thymectomy status, oncological features and surgical approach. AChR-Ab dosages were measured both before and after thymectomy. Linear regression models were applied to identify clinical determinants of AChR-Ab titers and the Cox regression model was fitted to estimate the factors associated with the risk of thymoma recurrence. Results: The study sample included 239 MG patients, 27 of whom experienced one or more recurrences (median follow-up time: 4.8 years). The AChR-Ab titers decreased after first thymectomy (P < 0.001); the decrease was more pronounced in female patients (P = 0.05), in patients diagnosed with MG at an older age (P = 0.003), and in those who had lower MG stage before surgery (P = 0.02) or higher Masaoka-Koga stage (P = 0.005). The risk of relapse was closely linked with the age of the patient, the Masaoka-Koga stage and the surgical approach. Conclusions: Presurgery levels of AChR-Ab or their change after surgery were not associated with thymoma recurrence. The reduction of AChR-Ab titers after thymectomy confirms an immunological role of thymoma in the pathogenesis of MG. Key points • Significant findings of the study: Young MG patients with an advanced Masaoka staging score of the primary tumor who underwent thymectomy with approaches different from sternotomy and VATS should be monitored for high risk of recurrence. • What this study adds: No other study has ever investigated the changes in AChR-Ab titers before and after thymectomy in a large cohort of TAMG 106

show abstract

Long-term outcomes of 307 patients after complete thymoma resection

Cited by 18 publications

References 28 publications

Clinical and laboratory features of seventy-eight UK patients with Good’s syndrome (thymoma and hypogammaglobulinaemia)

Clinical and laboratory features of seventy-eight UK patients with Good’s syndrome (thymoma and hypogammaglobulinaemia)

Using Machine Learning to Measure Relatedness Between Genes: A Multi-Features Model

Thymoma‐associated myasthenia gravis: Clinical features and predictive value of antiacetylcholine receptor antibodies in the risk of recurrence of thymoma

Contact Info

Product

Resources

About